• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    OptimizeRx Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    6/16/25 4:29:49 PM ET
    $OPRX
    Business Services
    Consumer Discretionary
    Get the next $OPRX alert in real time by email
    false 0001448431 0001448431 2025-06-11 2025-06-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of

    the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 11, 2025

     

    OptimizeRx Corporation

    (Exact name of registrant as specified in its charter)

     

    Nevada   001-38543   26-1265381
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    260 Charles Street, Suite 302, Waltham, MA   02453
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: 248-651-6568

     

                               Not Applicable                               

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, $0.001 Par Value   OPRX   The Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.07 Submission of Matters to a Vote of Security Holders.

     

    The Company’s 2025 Annual Meeting of Stockholders (“Annual Meeting”) was held on June 11, 2025. During the Annual Meeting, stockholders were asked to consider and vote upon three proposals: (1) to elect five directors, each to serve for a term that expires at the next annual meeting of stockholders and until his or her successor has been elected and qualified or until his or her earlier death, resignation or removal; (2) to approve, on an advisory basis, the compensation of the Company’s named executive officers; and (3) to ratify UHY LLP as the Company’s independent registered public accounting firm for the 2025 fiscal year ending on December 31, 2025.

     

    On the record date of April 29, 2025, there were 18,493,447 shares of the Company’s common stock issued and outstanding and entitled to vote at the Annual Meeting. For each proposal, the results of the stockholder voting were as follows:

     

    1.The following nominees were each elected to serve as director for a term that expires at the next annual meeting of stockholders and until his or her successor has been elected and qualified or until his or her earlier death, resignation or removal based upon the following votes:

     

    Nominee  Votes For   Votes Withheld   Broker
    Non-Votes
     
    Lynn O’Connor Vos   7,678,993    5,380,016    2,874,955 
    Catherine Klema   11,050,447    2,008,562    2,874,955 
    James Lang   8,291,707    4,767,302    2,874,955 
    Patrick Spangler   7,413,854    5,645,155    2,874,955 
    Gregory D. Wasson   8,809,348    4,249,661    2,874,955 

     

    2.The compensation of the Company’s named executive officers, as described in the proxy statement, was approved on an advisory basis based upon the following votes:

     

    Votes in Favor  Votes Against  Abstain  Broker Non-Votes
    5,443,720  3,857,653  3,757,636  2,874,955

     

    3.UHY LLP was ratified as the Company’s independent registered public accounting firm for the 2022 fiscal year based upon the following votes:

     

    Votes in Favor  Votes Against  Abstain
    15,162,244  745,489  26,231

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      OPTIMIZERX CORPORATION
         
    Date: June 16, 2025 By: /s/ Marion Odence-Ford
      Name:  Marion Odence-Ford
      Title: Chief Legal Officer

     

     

    2

     

     

    Get the next $OPRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OPRX

    DatePrice TargetRatingAnalyst
    1/8/2025$7.00 → $6.00Outperform → Sector Perform
    RBC Capital Mkts
    12/20/2024$5.50Equal-Weight
    Stephens
    7/25/2024$18.50Buy
    B. Riley Securities
    4/4/2024$15.00Mkt Outperform
    JMP Securities
    1/3/2024$15.00Equal Weight
    Barclays
    2/2/2023$30.00Buy
    B. Riley Securities
    11/1/2022$19.00Buy
    Stifel
    7/15/2022$38.00Outperform
    SVB Leerink
    More analyst ratings